Title 21 published on 2012-04-01
The following are only the Rules published in the Federal Register after the published date of Title 21.
For a complete list of all Rules, Proposed Rules, and Notices view the Rulemaking tab.
The Food and Drug Administration (FDA or “we”) is reopening the comment period for the interim final rule entitled “Use of Materials Derived From Cattle in Human Food and Cosmetics” that published in the Federal Register of July 14, 2004 (69 FR 42256). The interim final rule prohibited the use of certain cattle material to address the potential risk of bovine spongiform encephalopathy (BSE) in human food, including dietary supplements, and cosmetics. In the Federal Register of September 7, 2005 (70 FR 53063), we amended the interim final rule to make changes, including providing that the small intestine of cattle, formerly prohibited cattle material, could be used in human food and cosmetics if the distal ileum was removed by a specified procedure or one that the establishment could demonstrate is equally effective in ensuring complete removal of the distal ileum. Since 2005, peer-reviewed studies have been published showing the presence of infectivity in the proximal ileum, jejunum, ileocecal junction, and colon of cattle with BSE. Therefore, we are reopening the comment period for the interim final rule to give interested parties an opportunity to comment on the new studies concerning infectivity in parts of the small intestine other than the distal ileum.
This is a list of United States Code sections, Statutes at Large, Public Laws, and Presidential Documents, which provide rulemaking authority for this CFR Part.
This list is taken from the Parallel Table of Authorities and Rules provided by GPO [Government Printing Office].
It is not guaranteed to be accurate or up-to-date, though we do refresh the database weekly. More limitations on accuracy are described at the GPO site.
§ 355 - New drugs
21 USC § 355–1 - Risk evaluation and mitigation strategies
§ 355a - Pediatric studies of drugs
§ 355b - Adverse-event reporting
§ 355c - Research into pediatric uses for drugs and biological products
§ 355d - Internal committee for review of pediatric plans, assessments, deferrals, and waivers
§ 355e - Pharmaceutical security
§ 356 - Fast track products
21 USC § 356–1 - Accelerated approval of priority countermeasures
§ 356a - Manufacturing changes
§ 356b - Reports of postmarketing studies
§ 356c - Discontinuance of life saving product
§ 357 - Repealed.
§ 361 - Adulterated cosmetics
§ 362 - Misbranded cosmetics
§ 4332 - Cooperation of agencies; reports; availability of information; recommendations; international and national coordination of efforts
The following are ALL rules, proposed rules, and notices (chronologically) published in the Federal Register relating to 21 CFR 700 after this date.